Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Indication and core administration/dosing (maintenance once-daily via nebulizer/jet nebulizer using a unit-dose vial) are largely consistent with the provided label excerpts. Several additional claims (e.g., “improve lung function and breathing symptoms over time,” specific wording about “long-acting bronchodilator,” interchangeability limits, and example side effects) are not supported by the provided label sections; boxed warnings/contraindications and other critical safety domains were not evidenced in the supplied excerpts.
Category Scores
Accurate Statements
Yupelri is a prescription inhalation solution containing the drug revefenacin.
11 DESCRIPTION
Yupelri is made for use in a nebulizer.
2 DOSAGE AND ADMINISTRATION; 11 DESCRIPTION
Yupelri is used to treat chronic obstructive pulmonary disease (COPD).
1 INDICATIONS AND USAGE
Yupelri is intended for regular (maintenance) inhaled therapy, not for quick relief of sudden breathing problems.
1 INDICATIONS AND USAGE; 5 WARNINGS AND PRECAUTIONS (5.1); 17 PATIENT COUNSELING INFORMATION
Yupelri 175 mcg/3 mL comes in a unit dose.
11 DESCRIPTION; 3 DOSAGE FORMS AND STRENGTHS; 2 DOSAGE AND ADMINISTRATION
Yupelri is inhaled as a mist generated by a nebulizer.
2 DOSAGE AND ADMINISTRATION; 11 DESCRIPTION
Unsupported Statements
Yupelri is used for people with COPD as a long-term inhaled bronchodilator therapy.
Maintenance use is supported, but the provided excerpts do not explicitly support the “long-term” and/or “long-acting bronchodilator therapy” phrasing.
Yupelri is intended to improve lung function and breathing symptoms over time as part of ongoing COPD care.
The provided label excerpts describe maintenance treatment and non-use for acute symptoms, but do not state promises to improve lung function/breathing symptoms over time.
Yupelri (revefenacin) is a long-acting bronchodilator given via nebulization.
Nebulization and revefenacin are supported, but the provided excerpts do not explicitly confirm “long-acting bronchodilator” wording.
Yupelri is not interchangeable with other COPD inhalers or nebulizer solutions without a clinician’s guidance.
The provided excerpts do not address interchangeability/substitution with other COPD inhalers or nebulizer solutions.
Common side effects or concerns with inhaled bronchodilator therapies include dry mouth and cough.
The provided adverse-reaction excerpt does not list dry mouth or cough.
Contradictions
Important Omissions
Boxed warning status and/or any boxed warnings (if present) were not assessed because no boxed-warning label text was provided in the supplied excerpts.
Importance:
Moderate
Contraindications were not assessed because no contraindication label text was provided in the supplied excerpts.
Importance:
High
Critical safety precautions beyond non-rescue use (e.g., paradoxical bronchospasm, narrow-angle glaucoma, urinary retention, hypersensitivity) were not evaluated against the AI response in detail because the AI response only mentioned dry mouth/cough as side effects and did not address these label-listed clinically significant adverse reactions/precautions.
Importance:
Moderate
Storage/handling instructions were not assessed because no relevant label text was provided in the supplied excerpts.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Core maintenance/non-rescue framing aligns with labeling, reducing risk of inappropriate acute use. However, multiple claims are unsupported or overreaching (e.g., example side effects, long-acting/over-time benefit phrasing, and interchangeability statements). Additionally, contraindications and boxed-warning content were not evidenced from the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several label elements were either unsupported by the provided excerpts or not covered (e.g., “long-acting/over time benefit,” interchangeability limits, and dry mouth/cough as side effects).
Suggested Improvement
Restrict claims to the provided label-supported wording (maintenance COPD use; once-daily nebulized administration via standard jet nebulizer; not for acute rescue) and avoid adding benefits, pharmacologic duration (“long-acting”), interchangeability/substitution, or specific side-effect examples unless supported by the provided label sections. Include evaluation of contraindications/boxed warnings from the full label.